We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...

We recently published a list of 10 Stocks Kick Off Trading Week With Losses. In this article, we are going to take a look at ...

Baidu, Inc. (NASDAQ:BIDU) retreated on Tuesday, losing 7.51 percent to close at $90.16 apiece as investors unloaded ...

My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics ...

Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...

Tempus AI (NASDAQ: TEM) is a leader in precision medicine and artificial intelligence (AI) in the healthcare sector. Tempus ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Discover how 18F-FDG PET and PET/CT provide critical diagnostic accuracy for detecting high-grade transformations in chronic ...